Admen: fixing DDMAC is more vital than user fees

Share this article:
The Coalition for Healthcare Communication says it's too soon to talk about user fees to fund ad reviews through the FDA's DDMAC. An agreement reportedly reached between industry and the FDA would provide $6.25 million in user fees in fiscal year 2008 to fund review of TV spots before they air.

“New money for DDMAC reviews puts the cart before the horse,” according to Coalition for Healthcare Communication executive director John Kamp.

He said the coalition's citizen petition last March “outlined major concerns about the FDA's DTC review process that first must be addressed. For example, the process should be much more consistent and predictable. Once there is agreement that the DTC review process better meets the needs of patients and professionals, then everyone can better assess how best to fully fund it.”

At the time the petition was submitted, Kamp said the FDA's current ad rules require complicated information that many consumers cannot understand or use on a practical basis.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.